The abstract can be found on the ASH Annual Meeting website, https://submit.hematology.org/program/presentation/674309 ...

The combination of decitabine/cedazuridine and venetoclax achieved a 91% overall response rate in HR-MDS and CMML patients, with early responses observed. Median overall survival reached 30 months, ...

"We found that being treated at an academic center was associated with improved survival, suggesting that specialized care for CMML is an important aspect of treatment." — Douglas Tremblay, MD, Tisch ...

Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage oncology company dedicated to the discovery and development of novel biotherapeutics by ...

Dear Dr. Roach: My husband recently passed away one week after his 80th birthday. According to his death certificate, he died of lung cancer (not a surprise) and chronic myelomonocytic leukemia (CMML) ...

In this video, Douglas Tremblay, MD, discusses the results of a study into a first-line treatment of chronic myelomonocytic leukemia presented at ESMO Congress 2024. Tremblay, an assistant professor ...

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced that it will present ...

DEAR DR. ROACH: My husband recently passed away one week after his 80th birthday. According to his death certificate, he died of lung cancer (not a surprise) and chronic myelomonocytic leukemia (CMML) ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid ...

Learn how MDS/CMML-associated lupus differs from classic lupus and why clone-directed therapies may offer better outcomes. Find out more.